Metronidazol Serraclinics (Metronidazole)

Metronidazole enters anaerobic microorganisms and is reduced to nitro radicals. These reactive species damage microbial DNA and inhibit nucleic acid synthesis, leading to cell death while sparing aerobic cells that cannot perform the reduction.

The dosage of Metronidazol Serraclinics is determined by the prescribing clinician based on the specific infection, patient weight, renal function, and severity of disease. The product is supplied as an injectable solution for intravenous administration, and the prescriber sets the exact regimen.

Metronidazol Serraclinics is classified as Pregnancy Category B, indicating that animal studies have not shown risk but there are limited human data. It should be used only if the potential benefit outweighs the risk. The drug is excreted in breast milk, so breastfeeding mothers should discuss risks with their healthcare provider.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide. After submission, the sales team will verify trade or institutional credentials, then provide pricing, availability, shipping details (including cold‑chain if needed) and any required import documentation.

Metronidazol Serraclinics shares the same class mechanism as other nitroimidazoles like tinidazole, but it is formulated for intravenous use, offering rapid systemic exposure useful in severe infections. Oral nitroimidazoles are convenient for outpatient therapy, whereas the injectable form is preferred for hospitalized patients requiring immediate drug levels.

The product should be stored at 2‑8 °C in a refrigerator, protected from light. Do not freeze or shake the vial. If temperature excursions occur, discard the solution and obtain a new batch to ensure potency and safety.

Metronidazol Serraclinics is administered intravenously by a qualified healthcare professional. The solution is diluted in an appropriate compatible IV fluid and infused over the time period prescribed by the clinician, typically ranging from 30 minutes to several hours depending on the indication.

Serious adverse events include seizures, peripheral neuropathy, severe allergic reactions such as anaphylaxis, and hepatic dysfunction. Patients should be monitored for neurological symptoms, skin reactions, and liver function abnormalities, and therapy should be discontinued if any of these occur.

Metronidazol Serraclinics is contraindicated in patients with a known hypersensitivity to metronidazole or other nitroimidazole derivatives. It should also be avoided in individuals with severe hepatic impairment or those who cannot abstain from alcohol during therapy due to the risk of a disulfiram‑like reaction.